{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:59:27Z","timestamp":1790355567490,"version":"4.1.0"},"reference-count":57,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Autoimmune hemolytic anemia (AIHA) is most often idiopathic. However, in recent years, AIHA has been noted with increased incidence in patients receiving purine nucleoside analogues for hematologic malignancies; it has also been described as a complication of blood transfusion in patients who have also had alloimmunization. As the technology of hematopoietic stem cell transplantation has become more widespread, immune hemolysis in the recipients of ABO-mismatched products has become better recognized. The syndrome is caused by passenger lymphocytes transferred from the donor and, although transient, can be quite severe. A similar syndrome has been observed in recipients of solid organ transplants when there is ABO-incompatibility between donor and recipient.<\/jats:p>\n               <jats:p>Venous thromboembolism is a little-recognized, though likely common, complication of AIHA, and may in some instances be related to coexistent antiphospholipid antibodies. While AIHA is a well-documented complication of malignant lymphoproliferative disorders, lymphoproliferative disorders may also paradoxically appear as a consequence of AIHA.<\/jats:p>\n               <jats:p>A number of newer options are available for treatment of AIHA in patients refractory to corticosteroids and splenectomy. Newer immunosuppressives such as mycophenolate mofetil may have a role in such cases. Considerable experience has been accumulating in the last few years with monoclonal antibody therapy, mainly rituximab, in difficult AIHA cases; it appears to be a safe and effective option.<\/jats:p>","DOI":"10.1182\/asheducation-2009.1.80","type":"journal-article","created":{"date-parts":[[2009,12,11]],"date-time":"2009-12-11T20:35:31Z","timestamp":1260563731000},"page":"80-86","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":56,"title":["Immune hemolytic anemia\u2014selected topics"],"prefix":"10.1182","volume":"2009","author":[{"given":"Philip C.","family":"Hoffman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111702440998500_R1","doi-asserted-by":"crossref","unstructured":"Myint H, Copplestone JA, Orchard J, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol. 1995;91:341\u2013344.","DOI":"10.1111\/j.1365-2141.1995.tb05300.x"},{"key":"2019111702440998500_R2","doi-asserted-by":"crossref","unstructured":"Weiss RB, Freiman J, Kweder SL, Diehl LF, Byrd JC. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol. 1998;16:1885\u20131889.","DOI":"10.1200\/JCO.1998.16.5.1885"},{"key":"2019111702440998500_R3","doi-asserted-by":"crossref","unstructured":"Fleischman RA, Croy D. Acute onset of severe autoimmune hemolytic anemia after treatment with 2-chlorodeoxyadenosine for chronic lymphocytic leukemia. Am J Hematol. 1995;48:293.","DOI":"10.1002\/ajh.2830480423"},{"key":"2019111702440998500_R4","doi-asserted-by":"crossref","unstructured":"Aslan DL, Peterson BA, Long-Tsai M, Eastlund T. Early-onset autoimmune hemolytic anemia after cladribine therapy for Waldenstrom\u2019s macroglobulinemia. Transfusion. 2006;46:90\u201394.","DOI":"10.1111\/j.1537-2995.2006.00678.x"},{"key":"2019111702440998500_R5","doi-asserted-by":"crossref","unstructured":"Byrd JC, Hertler AA, Weiss RB, Freiman J, Kweder SL, Diehl LF. Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia. Ann Oncol. 1995;6:300\u2013301.","DOI":"10.1093\/oxfordjournals.annonc.a059162"},{"key":"2019111702440998500_R6","doi-asserted-by":"crossref","unstructured":"Dearden C, Wade R, Else M, et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood. 2008;111:1820\u20131826.","DOI":"10.1182\/blood-2007-07-101303"},{"key":"2019111702440998500_R7","doi-asserted-by":"crossref","unstructured":"Borthakur G, O\u2019Brien S, Wierda WG, et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab\u2014incidence and predictors. Br J Haematol. 2007;136:800\u2013805.","DOI":"10.1111\/j.1365-2141.2007.06513.x"},{"key":"2019111702440998500_R8","doi-asserted-by":"crossref","unstructured":"Paydas S. Fludarabine-induced hemolytic anemia: successful treatment by rituximab. Hematol J. 2004;5:81\u201383.","DOI":"10.1038\/sj.thj.6200339"},{"key":"2019111702440998500_R9","doi-asserted-by":"crossref","unstructured":"Young PP, Uzieblo A, Trulock E, Lublin DM, Goodnough LT. Autoantibody formation after alloimmunization: are blood transfusions a risk factor for autoimmune hemolytic anemia? Transfusion. 2004;44:67\u201372.","DOI":"10.1046\/j.0041-1132.2003.00589.x"},{"key":"2019111702440998500_R10","doi-asserted-by":"crossref","unstructured":"Garratty G. Autoantibodies induced by blood transfusion. Transfusion. 2004;44:5\u20139.","DOI":"10.1111\/j.0041-1132.2004.00658.x"},{"key":"2019111702440998500_R11","doi-asserted-by":"crossref","unstructured":"Aygun B, Padmanabhan S, Paley C, Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion. 2002;42;37\u201343.","DOI":"10.1046\/j.1537-2995.2002.00007.x"},{"key":"2019111702440998500_R12","doi-asserted-by":"crossref","unstructured":"Castellino SM, Combs MR, Zimmerman SA, Issitt PD, Ware RE. Erythrocyte autoantibodies in paediatric patients with sickle cell disease receiving transfusion therapy: frequency, characteristics and significance. Br J Haematol. 1999;104:189\u2013194.","DOI":"10.1046\/j.1365-2141.1999.01127.x"},{"key":"2019111702440998500_R13","doi-asserted-by":"crossref","unstructured":"Singer ST, Wu V, Mignacca R, Kuypers FA, Morel P, Vinchinsky EP. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly asian descent. Blood. 2000;96:3369\u20133373.","DOI":"10.1182\/blood.V96.10.3369"},{"key":"2019111702440998500_R14","doi-asserted-by":"crossref","unstructured":"Petz LD. Bystander immune cytolysis. Transfus Med Rev. 2006;20:110\u2013140.","DOI":"10.1016\/j.tmrv.2005.11.002"},{"key":"2019111702440998500_R15","doi-asserted-by":"crossref","unstructured":"Win N, New H, Lee E, de la Fuente J. Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review. Transfusion. 2008;48:1231\u20131238.","DOI":"10.1111\/j.1537-2995.2008.01693.x"},{"key":"2019111702440998500_R16","doi-asserted-by":"crossref","unstructured":"Bolan CD, Childs RW, Procter JL, Barrett A.J, Leitman SF. Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility. Br J Haematol. 2001;112:787\u2013795.","DOI":"10.1046\/j.1365-2141.2001.02587.x"},{"key":"2019111702440998500_R17","doi-asserted-by":"crossref","unstructured":"Worel N, Greinix HT, Keil F, et al. Severe immune hemolysis after minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation occurs more frequently after nonmyeloablative than myeloablative conditioning. Transfusion. 2002;42:1293\u20131301.","DOI":"10.1046\/j.1537-2995.2002.00209.x"},{"key":"2019111702440998500_R18","doi-asserted-by":"crossref","unstructured":"Petz LD. Immune hemolysis associated with transplantation. Semin Hematol. 2005;42:145\u2013155.","DOI":"10.1053\/j.seminhematol.2005.05.017"},{"key":"2019111702440998500_R19","doi-asserted-by":"crossref","unstructured":"Franchini M, Gandini G, Aprili G. Non-ABO red blood cell alloantibodies following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;33:1169\u20131172.","DOI":"10.1038\/sj.bmt.1704524"},{"key":"2019111702440998500_R20","doi-asserted-by":"crossref","unstructured":"Worel N, Greinix HT, Supper V, et al. Prophylactic red blood cell exchange for prevention of severe immune hemolysis in minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation after reduced-intensity conditioning. Transfusion. 2007;47:1494\u20131502.","DOI":"10.1111\/j.1537-2995.2007.01289.x"},{"key":"2019111702440998500_R21","doi-asserted-by":"crossref","unstructured":"Tiplady CW, Fitzgerald JM, Jackson GH, Conn JS, Proctor SJ. Massive haemolysis in a group A recipient of a group O peripheral blood stem cell allogeneic transplant. Transfus Med. 2001;11:455\u2013458.","DOI":"10.1046\/j.1365-3148.2001.00334.x"},{"key":"2019111702440998500_R22","doi-asserted-by":"crossref","unstructured":"O\u2019Brien TA, Eastlund T, Peters C, et al. Autoimmune haemolytic anaemia complicating haematopoietic cell transplantation in paediatric patients: high incidence and significant mortality in unrelated donor transplants for non-malignant diseases. Br J Haematol. 2004;127:67\u201375.","DOI":"10.1111\/j.1365-2141.2004.05138.x"},{"key":"2019111702440998500_R23","unstructured":"Drobyski WR, Potluri J, Sauer D, Gottschall JL. Autoimmune hemolytic anemia following T cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplant. 1996;17:1093\u20131099."},{"key":"2019111702440998500_R24","doi-asserted-by":"crossref","unstructured":"Chen FE, Owen I, Savage D, et al. Late onset haemolysis and red cell autoimmunisation after allogeneic bone marrow transplant. Bone Marrow Transplant. 1997;19:491\u2013495.","DOI":"10.1038\/sj.bmt.1700677"},{"key":"2019111702440998500_R25","doi-asserted-by":"crossref","unstructured":"Sevilla J, Gonzalez-Vicent M, Madero L, Diaz MA. Acute autoimmune hemolytic anemia following unrelated cord blood transplantation as an early manifestation of chronic graft-versus-host disease. Bone Marrow Transplant. 2001;28:89\u201392.","DOI":"10.1038\/sj.bmt.1703087"},{"key":"2019111702440998500_R26","doi-asserted-by":"crossref","unstructured":"Urban C, Benesch M, Sovinz P, Schwinger W, Lackner H. Fatal Evans\u2019 syndrome after matched unrelated donor transplantation for hyper-IgM syndrome. Eur J Haematol. 2004;72:444\u2013447.","DOI":"10.1111\/j.1600-0609.2004.00256.x"},{"key":"2019111702440998500_R27","doi-asserted-by":"crossref","unstructured":"Corti P, Bonanomi S, Vallinoto C, et al. Rituximab for immune hemolytic anemia following T- and B-cell-depleted hematopoietic stem cell transplantation. Acta Haematol. 2003;109:43\u201345.","DOI":"10.1159\/000067271"},{"key":"2019111702440998500_R28","doi-asserted-by":"crossref","unstructured":"Ship A, May W, Lucas K. Anti-CD20 monoclonal antibody therapy for autoimmune hemolytic anemia following T cell-depleted, haplo-identical stem cell transplantation. Bone Marrow Transplant. 2002;29:365\u2013366.","DOI":"10.1038\/sj.bmt.1703371"},{"key":"2019111702440998500_R29","doi-asserted-by":"crossref","unstructured":"Ramsey G. Red cell antibodies arising from solid organ transplants. Transfusion. 1991;31:76\u201386.","DOI":"10.1046\/j.1537-2995.1991.31191096190.x"},{"key":"2019111702440998500_R30","doi-asserted-by":"crossref","unstructured":"Salerno CT, Burdine J, Perry EH, Kshettry VR, Hertz MI, Bolman RM 3rd. Donor-derived antibodies and hemolysis after ABO-compatible but nonidentical heart-lung and lung transplantation. Transplantation. 1998;65:261\u2013264.","DOI":"10.1097\/00007890-199801270-00021"},{"key":"2019111702440998500_R31","doi-asserted-by":"crossref","unstructured":"Triulzi DJ, Shirey RS, Ness PM, Klein AS. Immunohematologic complications of ABO-unmatched liver transplants. Transfusion. 1992;32:829\u2013833.","DOI":"10.1046\/j.1537-2995.1992.32993110754.x"},{"key":"2019111702440998500_R32","doi-asserted-by":"crossref","unstructured":"Ainsworth CD, Crowther MA, Treleaven D, Evanovitch D, Webert KE, Blajchman MA. Severe hemolytic anemia post-renal transplantation produced by donor anti-D passenger lymphocytes: case report and literature review. Transfus Med Rev. 2009;23:155\u2013159.","DOI":"10.1016\/j.tmrv.2008.12.005"},{"key":"2019111702440998500_R33","doi-asserted-by":"crossref","unstructured":"Cserti-Gazdewich CM, Waddell TK, Singer LG, et al. Passenger lymphocyte syndrome with or without immune hemolytic anemia in all Rh-positive recipients of lungs from rhesus alloimmunized donors: three new cases and a review of the literature. Transfus Med Rev. 2009;23:134\u2013145.","DOI":"10.1016\/j.tmrv.2008.12.003"},{"key":"2019111702440998500_R34","doi-asserted-by":"crossref","unstructured":"Shortt J, Westall GP, Roxby D, et al. A \u2018dangerous\u2019 group O donor: severe hemolysis in all recipients of organs from a donor with multiple red cell alloantibodies. Am J Transplant. 2008;8:711\u2013714.","DOI":"10.1111\/j.1600-6143.2007.02113.x"},{"key":"2019111702440998500_R35","doi-asserted-by":"crossref","unstructured":"Yazer MH, Triulzi DJ. Immune hemolysis following ABO-mismatched stem cell or solid organ transplantation. Curr Opin Hematol. 2007;14:664\u2013670.","DOI":"10.1097\/MOH.0b013e3282e9a576"},{"key":"2019111702440998500_R36","unstructured":"Allgood JW, Chaplin H Jr. Idiopathic acquired autoimmune hemolytic anemia. A review of forty-seven cases treated from 1955 through 1965. Am J Med. 1967;43:254\u2013273."},{"key":"2019111702440998500_R37","doi-asserted-by":"crossref","unstructured":"Pullarkat V, Ngo M, Iqbal S, Espina B, Liebman HA. Detection of lupus anticoagulant identifies patients with autoimmune haemolytic anaemia at increased risk for venous thromboembolism. Br J Haematol. 2002;118:1166\u20131169.","DOI":"10.1046\/j.1365-2141.2002.03729.x"},{"key":"2019111702440998500_R38","doi-asserted-by":"crossref","unstructured":"Kokori SI, Ioannidis JP, Voulgarelis M, Tzioufas AG, Moutsopoulos HM. Autoimmune hemolytic anemia in patients with systemic lupus erythematosus. Am J Med. 2000;108:198\u2013204.","DOI":"10.1016\/S0002-9343(99)00413-1"},{"key":"2019111702440998500_R39","doi-asserted-by":"crossref","unstructured":"Hendrick AM. Auto-immune haemolytic anaemia\u2014a high-risk disorder for thromboembolism? Hematology. 2003;8:53\u201356.","DOI":"10.1080\/1024533021000059474"},{"key":"2019111702440998500_R40","unstructured":"Sallah S, Wan JY, Hanrahan LR. Future development of lymphoproliferative disorders in patients with autoimmune hemolytic anemia. Clin Cancer Res. 2001;7:791\u2013794."},{"key":"2019111702440998500_R41","doi-asserted-by":"crossref","unstructured":"Landgren O, Gridley G, Check D, Caporaso NE, Morris Brown L. Acquired immune-related and inflammatory conditions and subsequent chronic lymphocytic leukaemia. Br J Haematol. 2007;139:791\u2013798.","DOI":"10.1111\/j.1365-2141.2007.06859.x"},{"key":"2019111702440998500_R42","doi-asserted-by":"crossref","unstructured":"Anderson LA, Gadalla S, Morton LM, et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer. 2009;125:398\u2013405.","DOI":"10.1002\/ijc.24287"},{"key":"2019111702440998500_R43","doi-asserted-by":"crossref","unstructured":"Ekstrom Smedby K, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008;111:4029\u20134038.","DOI":"10.1182\/blood-2007-10-119974"},{"key":"2019111702440998500_R44","doi-asserted-by":"crossref","unstructured":"Anderson LA, Pfeiffer RM, Landgren O, Gadalla s, Berndt SI, Engels EA. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer. 2009;100:822\u2013828.","DOI":"10.1038\/sj.bjc.6604935"},{"key":"2019111702440998500_R45","doi-asserted-by":"crossref","unstructured":"Flores G, Cunningham-Rundles C, Newland AC, Bussel JB. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am J Hematol. 1993;44:237\u2013242.","DOI":"10.1002\/ajh.2830440404"},{"key":"2019111702440998500_R46","doi-asserted-by":"crossref","unstructured":"Ahn YS. Efficacy of danazol in hematologic disorders. Acta Haematol. 1990;84:122\u2013129.","DOI":"10.1159\/000205048"},{"key":"2019111702440998500_R47","doi-asserted-by":"crossref","unstructured":"Pignon JM, Poirson E, Rochant H. Danazol in autoimmune haemolytic anaemia. Br J Haematol. 1993;83:343\u2013345.","DOI":"10.1111\/j.1365-2141.1993.tb08293.x"},{"key":"2019111702440998500_R48","doi-asserted-by":"crossref","unstructured":"Howard J, Hoffbrand AV, Prentice HG, Mehta A. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br J Haematol. 2002;117:712\u2013715.","DOI":"10.1046\/j.1365-2141.2002.03430.x"},{"key":"2019111702440998500_R49","doi-asserted-by":"crossref","unstructured":"Kotb R, Pinganaud C, Trichot C, et al. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol. 2005;75:60\u201364.","DOI":"10.1111\/j.1600-0609.2005.00437.x"},{"key":"2019111702440998500_R50","doi-asserted-by":"crossref","unstructured":"Zecca M, De Stefano P, Nobili B, Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood. 2001;97:3995\u20133997.","DOI":"10.1182\/blood.V97.12.3995"},{"key":"2019111702440998500_R51","doi-asserted-by":"crossref","unstructured":"Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc. 2003;78:1340\u20131346.","DOI":"10.4065\/78.11.1340"},{"key":"2019111702440998500_R52","doi-asserted-by":"crossref","unstructured":"Ramanathan S, Koutts J, Hertzberg MS. Two cases of refractory warm autoimmune hemolytic anemia treated with rituximab. Am J Hematol. 2005;78:123\u2013126.","DOI":"10.1002\/ajh.20220"},{"key":"2019111702440998500_R53","doi-asserted-by":"crossref","unstructured":"Gupta N, Kavuru S, Patel D, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia. 2002;16:2092\u20132095.","DOI":"10.1038\/sj.leu.2402676"},{"key":"2019111702440998500_R54","doi-asserted-by":"crossref","unstructured":"D\u2019Arena G, Laurenti L, Capalbo S, et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol. 2006;81:598\u2013602.","DOI":"10.1002\/ajh.20665"},{"key":"2019111702440998500_R55","doi-asserted-by":"crossref","unstructured":"Willis F, Marsh JC, Bevan DH, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001;114:891\u2013898.","DOI":"10.1046\/j.1365-2141.2001.03039.x"},{"key":"2019111702440998500_R56","doi-asserted-by":"crossref","unstructured":"Karlsson C, Hansson L, Celsing F, Lundin J. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia. 2007;21:511\u2013514.","DOI":"10.1038\/sj.leu.2404512"},{"key":"2019111702440998500_R57","doi-asserted-by":"crossref","unstructured":"Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol. 2008;141:149\u2013169.","DOI":"10.1111\/j.1365-2141.2008.07054.x"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2009\/1\/80\/645388\/080_086ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2009\/1\/80\/645388\/080_086ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T07:44:39Z","timestamp":1573976679000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2009\/1\/80\/19788\/Immune-hemolytic-anemiaselected-topics"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2009.1.80","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,1]]}}}